ADIPOQ and metabolic dysfunction-associated steatotic liver disease: A larger study to assess the correlation of plasma adiponectin and urine ACR with CIMT in dyslipidemic and non-dyslipidemic patients with NAFLD will help to explore the antiatherogenic role of adiponectin and the value of albuminuria as a risk indicator in those patients.